Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma.
Cardiovasc Hematol Disord Drug Targets
; 21(3): 206-209, 2021.
Article
in English
| MEDLINE | ID: covidwho-1408611
ABSTRACT
BACKGROUND:
COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits. CASE DESCRIPTION We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.CONCLUSION:
There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Venous Thromboembolism
/
COVID-19
Type of study:
Case report
/
Cohort study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
Language:
English
Journal:
Cardiovasc Hematol Disord Drug Targets
Journal subject:
Vascular Diseases
/
Cardiology
/
Hematology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1871529X21666210914113752
Similar
MEDLINE
...
LILACS
LIS